Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects Observed in Chemoprevention Trials Using 5-Alpha-Reductase Inhibitors (Q57565209)
Jump to navigation
Jump to search
scientific article published on 13 April 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Low-Activity V89L Variant in SRD5A2 Is Associated with Aggressive Prostate Cancer Risk: An Explanation for the Adverse Effects Observed in Chemoprevention Trials Using 5-Alpha-Reductase Inhibitors |
scientific article published on 13 April 2007 |
Statements
Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors (English)
Abdel-Rahmène Azzouzi
Nathalie Nicolaiew
Philippe Mangin
Luc Cormier
Georges Fournier
Antoine Valeri
13 April 2007